The FDA’s approval was based on a study of 11,400 people age 12 and older that compared the new low-dose vaccine with Moderna ...

The FDA's approval was based on a study of 11,400 people age 12 and older that compared the new low-dose vaccine with Moderna ...

Moderna's next COVID-19 vaccine has received Food and Drug Administration approval, albeit with restrictions not placed on ...

The FDA has approved Nuvaxovid to prevent COVID-19 in adults 65 years and older and high-risk individuals 12 through 64 years.

Novavax's full FDA approval for NUVAXOVID is a transformative milestone, unlocking a $175M Sanofi payment and validating ...

Novavax originally showed its vaccine was safe and effective in a 30,000-person clinical trial. The FDA had been on track to ...

The FDA has approved the Novavax COVID-19 vaccine, called Nuvaxovid, mainly for adults 65 or older, but people ages 12 to 64 ...

Novavax's shot is now fully approved in the U.S. Since 2022, the vaccine has been used under an emergency use authorization.

Novavax makes the nation’s only traditional protein-based coronavirus vaccine – and until now it had emergency authorization from FDA for use in anyone 12 and older.

The US Food and Drug Administration on Friday approved Novavax’s COVID-19 vaccine, but placed additional conditions on individuals who would be able to receive the vaccine. According to the approval ...

The FDA has approved Novavax's COVID-19 vaccine, Nuvaxovid, but with restrictions. It's authorized for individuals 65 and older, and those aged 12-64 with underlying conditions increasing their risk ...